



LASA SUPERGENERICS LIMITED

CORPORATE OFFICE: B/207, City Point, Near Kohinoor Hotel, J B Nagar (Chakala) Metro Station, Andheri (E), Mumbai – 400059, Maharashtra, India.
Tel: 022-4970 1092. Email: mail@lasalabs.com, Website: www.lasalabs.com

Ref. No.: LASA/SE/20-21/23

Thursday, August 06, 2020

To, Corporate Services Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE CODE –540702	To, Corporate Services Department National Stock Exchange of India Limited “Exchange Plaza”, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. NSE CODE: LASA
--	--

Dear Sir/Madam,

Subject: Media Release

Attached is the copy of Media Release titled “ **LASA SUPERGENERICS Q1FY21 PAT AT 5.37CRS, UP437% YOY**” issued by the company.

You are requested to take the same on your record.

Yours Sincerely
FOR LASA SUPERGENERICS LIMITED

NIDHI KULSHRESHTHA
COMPANY SECRETARY AND COMPLIANCE OFFICER



Media Release

LASA SUPERGENERICS Q1FY21 PAT AT 5.37CRS, UP437% YOY

Mumbai, 6th August 2020: Lasa Supergenerics Limited, a vertically integrated group spanning the entire animal and human healthcare value chain has announced its financial results for the first quarter ended June 30th 2020 (Q1FY21)

Q1FY21 performance overview compared with Q4FY20

- Revenues from operations stood at Rs. 54.60 crore as against Rs. 48.58crore in Q4FY20
- EBITDA of Rs. 12.20 crore as compared to Rs. 9.01 crore in Q4FY20
- EBITDA margins at 22.34%
- PAT stood at Rs. 5.37crore as compared to Rs.2.61 crore in Q4FY20
- EPS for Q1FY21 stood at Rs. 1.32

Q1FY21 performance overview compared with Q1FY20

- Revenues from operations stood at Rs. 54.60crore as against Rs. 38.98crore in Q1FY20
- EBITDA of Rs. 12.20crore as compared to Rs. 5.06 crore in Q1FY20
 - EBITDA margins at 22.34% as against 12.98% in Q1FY20
- PAT stood at Rs.5.37crore as against a loss of **Rs.1.07 crore**
- EPS for Q1FY21 stood at Rs. 1.32 as compared to Rs. 0.47 in Q1FY20

For first quarter ended June 30th 2020

Revenues from operations for the first quarter ended June 30th, 2020(Q1FY21) stood at Rs. 54.60crore.

The Company reported Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) of Rs. 12.20crore in Q1FY21, as against Rs 9.01crore in Q4FY20; up 35.4%. The Company's EBITDA margin stood at22.34%

The Company reported PAT of Rs. 5.37crore for Q1FY21.The Company's PAT margin stood at 9.84%

Earnings per share (EPS) for the quarter ended Q1FY21 stood at Rs1.32

The Finance cost reduced by 45% Q-o-Q from Rs. 2.29 crore in Q4FY20 to Rs. **1.26** crore in Q1FY21

Commenting on the performance, Dr. OmkarHerlekar, Chairman – LasaSupergenerics Limited, said,



“We have reported a good performance in our business in Q1 FY21 despite significant disruptions and ambiguity in the business environment. We are confident that the Company under its strong leadership and planned strategies will navigate through these difficult times. We have also substantially brought down the debt.

About LasaSupergenerics Limited (www.lasalabs.com/; BSE: 540702; NSE: LASA)

Incorporated in 2011, Lasa Supergenerics Limited is a globally well trusted brand with high quality products, accepted by large companies across the globe. Our Company is the pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. The Company has its unit with state of art manufacturing facilities located at Mahad& Chiplun, Maharashtra with a total installed capacity of 4,300 MT. The Company has over 25% of APIs exported to counties like Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea, Pakistan etc.

For more information contact:

Mr. Hitesh Wadhvani
LasaSupergenerics Ltd.
Tel: 7798888147
E-mail: hitesh@lasalabs.com

Mr Shahab Shaikh / Amruta Desai
Concept PR
+91 9320897525/ +91 9867891235
shahab@conceptpr.com/amruta@conceptpr.com

DISCLAIMER:

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. LasaSupergenerics Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.